

**FRANKLIN G. MILLER, Ph.D.**

3910 Underwood Street  
Chevy Chase, MD 20815  
Phone: (301) 656-8757  
E-mail: fgm2002@med.cornell.edu

EDUCATION

- 1977 Columbia University, Ph.D. in philosophy.  
Dissertation: *A Theory of Political Obligation*,  
an inquiry into the grounds for a moral obligation to obey the law;  
awarded Distinction.  
Specialized in ethics and political philosophy.
- 1971 Columbia College, B.A., majored in philosophy.

PROFESSIONAL EXPERIENCE

Current Position

- 2014- Professor of Medical Ethics in Medicine (Courtesy) Weill Cornell Medical College
- 2015- Adjunct Faculty, Department of Bioethics, National Institutes of Health

Previous Position

- 1999-2015 Senior faculty, Department of Bioethics, National Institutes of Health; special expert Intramural Research Program, National Institute of Mental Health.

Teaching

- 2001-2003 Bioethics seminar for Faculty Associates, Division of Medical Ethics, Cornell University Medical School
- June 2001, June 2007 Small group leader, Kennedy Institute of Ethics, Intensive Bioethics Course
- 1999-2009 Seminar for NIMH psychiatric research fellows on the ethics of psychiatric research. Awarded 2002 Alan Stoudemire Award for Innovation and Excellence in Consultation-Liaison Education.
- 1990-1999 Associate Professor of Medical Education (from 7/1/97)

University of Virginia, Center for Biomedical Ethics.  
Courses taught included: Foundations of Bioethics, Bioethics Internship Seminar, Introduction to Clinical Ethics, Clinical Ethics Proseminar, Figures and Traditions in Philosophical and Religious Ethics, History of Bioethics via the Great Cases, and Issues in Bioethics.

1998 The New York Hospital-Cornell Medical Center, Advanced Seminar in Medical Ethics.

1975-76 Kean College of New Jersey, taught course on philosophy of law.

1973-74 Columbia University, School of General Studies, taught course on introduction to moral philosophy.

#### Consultation in Biomedical Ethics

2017- Member, Ethics Advisory Committee, Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania

2016-17 Member of Planning Group and Writing Group for NIH Consultation on the Ethics of ZIKV Human Challenge Trials

2015- Ethics consultant, Jewish Social Service Agency Hospice Program

2012-2015 Member of Data Safety and Monitoring Board, NIMH Intramural Research Program

9/1/12-2013 Member of Data Safety and Monitoring Board, PITCH-HF, National Heart, Lung, and Blood Institute

3/5/08-2010 Member of Protocol Review Committee, Cardiothoracic Surgical Trials Network, National Heart, Lung, and Blood Institute

2/8/08 Member of NIH Study Section, Research on Ethical Issues in Human Studies

2007-2012 Member of Data Safety Monitoring Committee, Comparison of Age-related Macular Degeneration Treatment Trials, National Eye Institute

1991-2006 Member of Institutional Review Board, National Institute of Mental Health.

2007-2012 Member of CNS Institutional Review Board, Intramural Research Program, National Institutes of Health

- 2012-2014 Member of NHLBI Institutional Review Board,  
Intramural Research Program, National Institutes of Health
- 1990-2010 Member of Ethics Committee, Clinical Center, National Institutes of Health.
- 2001-2004 Member of Data Safety and Monitoring Board, National Institute of Mental  
Health
- 1/9/04 Member, Protocol Review Committee for the Coronary Revascularization in  
Diabetic Patients with Multivessel Disease Trial, sponsored by the National Heart,  
Lung, and Blood Institute.
- 1995-2003 Member of Ethics Committee, Jewish Social Service Agency of Metropolitan  
Washington, Home Care Services and Hospice.
- 1997-2000 Member of Data Safety and Monitoring Board for Clinical Studies of Chronic  
Lyme Disease, sponsored by National Institute of Allergy and Infectious  
Diseases.
- 1996-1998 Consultant Ethicist to The New York Hospital: consultation in research and  
program planning concerning improving the care of hospitalized dying  
patients.
- 4/6/98 Member of NIAID Expert Panel on Effects of Donor Pool Size on Safety and  
Efficacy of Immunoglobulin Products.
- 1993-97 Member of Data Safety and Monitoring Board for clinical trial of HIV  
Hyperimmune globulin in HIV-infected pregnant woman to prevent vertical  
transmission of HIV, sponsored by National Heart, Lung, and Blood Institute.
- 6/26/95 Member of Ad Hoc Panel to Review Randomized Clinical Trial of T-cell  
Depletion in Unrelated Donor Marrow Transplantation, convened by National  
Heart, Lung, and Blood Institute.
- 1988-90 Counselor to Biomedical Ethics Program, University of Virginia: help in  
organizing a Center for Biomedical Ethics, program development, and  
financial planning.
- 1985-90 Member of Institutional Review Board, National Institute of Child Health and  
Human Development.

## Planning and Program Development

1977-82 Vera Institute of Justice, New York City, Project Director from 1979-82, Senior Planner from 1977-79: responsible for planning, technical assistance, program development, and research in child welfare and juvenile justice.

## PUBLICATIONS

### Articles

**Miller FG.** Challenging the conventional wisdom: from philosophy to bioethics. *Perspectives in Biology and Medicine* 2017;60:3-18.

**Miller FG.** Should a legal option of physician-assisted death include those who are “tired of life”? *Perspectives in Biology and Medicine.* 2016;59:351-63.

**Miller FG.** Henry Beecher and consent to research: a critical re-examination. *Perspectives in Biology and Medicine* 2016;59:78-94.

Barnhill A, Joffe S, **Miller FG.** The ethics of infection challenges in primates. *Hastings Center Report* 2016;46(4):20-26.

Nugent AC, . . . **Miller FG,** et al. Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data for 12 years of clinical trials at the US National Institute of Mental Health. *Lancet Psychiatry* 2016;3:436-42.

Cassel JB, . . . **Miller FG.** Phase 1 cancer trials and palliative care: antagonism, irrelevance, or synergy? *Journal of Pain and Symptom Management* 2016;52:437-45.

Rid A, **Miller FG.** Rationale for the Ebola “ring vaccination” trial design. *American Journal of Public Health* 2016;106:432-5.

**Miller FG.** On changing one’s mind in bioethics, *Perspectives in Biology and Medicine* 2015;58:507-17.

Colloca L, . . . **Miller FG,** et al. Vasopressin boosts placebo effects in women: a randomized trial. *Biological Psychiatry* 2016;79:794-802.

Kim S, **Miller FG**. Ethical complexities in standard of care randomized trials: a case study of morning versus nighttime dosing of blood pressure drugs. *Clinical Trials* 2015;12:557-63.

Nayak R, Wendler D, **Miller FG**, Kim S. Pragmatic trials without standard informed consent: a national survey. *Annals of Internal Medicine* 2015;163:356-64.

Dickert N, **Miller FG**. Involving patients in enrollment decisions for acute myocardial infarction trials. *BMJ* 2015;July 29; 351:h3791.

Kaptchuk TJ, **Miller FG**. Placebo effects in medicine. *New England Journal* 2015;373:8-9.

Barnhill A, **Miller FG**. The ethics of placebo treatments in clinical practice: a reply to Glackin. *Journal of Medical Ethics* 2015;41:673-76.

du Toit J, **Miller FG**. The ethics of continued life-sustaining treatment for those diagnosed as brain dead. *Bioethics* 2016;30:151-8.

Miller LR, **Miller FG**. Understanding placebo effects: implications for nursing practice. *Nursing Outlook* 2015;63:601-6.

**Miller FG**, Kim SYH. Personal care in learning health care systems. *Kennedy Institute of Ethics Journal* 2015;25:419-35.

Kim S, **Miller FG**. Varieties of standard-of-care treatment randomized trials: ethical implications. *JAMA* 2015;313:895-6.

Annoni M, **Miller FG**. Placebos in clinical practice: an overview, *Douleur et Analgesie*, in press.

Annoni M, **Miller FG**. The ethics of therapeutic communication: a pragmatic perspective, *Kennedy Institute of Ethics* 2016;26: 79-103.

**Miller FG**, Joffe S, Kesselheim A. Evidence, errors, and ethics. *Perspectives in Biology and Medicine* 2014;57:299-307.

Colloca L, Jonas WB, Killen J, **Miller FG**, Shurtleff D. Reevaluating the placebo effect in medical practice. *Z Psychology* 2014;222(3):124-7.

Kim S, **Miller FG**. Waivers and alterations to consent in pragmatic trials. *IRB* 2016;38(1):1-5.

Gelinas L, Wertheimer A, **Miller FG**. When and why is research without consent permissible. *Hastings Center Report* 2016;46(2):35-43.

Barnhill A, **Miller FG**. Placebo and deception: a commentary. *Journal of Medicine and Philosophy* 2015;40:69-82.

Moustgaard H, . . . **Miller FG**, et al. Outcome classification in randomised clinical trials: definitions of subjects and objective outcomes differed in methods publications but were absent from trial reports. *Journal of Clinical Epidemiology* 2014;67:1327-34.

Geers A, **Miller FG**. Understanding and translating knowledge about placebo effects: the contribution of psychology. *Current Opinion in Psychiatry* 2014;27:326-31.

Joffe S, **Miller FG**. The ethics of cancer clinical trials in low-resource settings. *Journal of Clinical Oncology* 2014;32:3192-6.

Truog RD, **Miller FG**. The meaning of brain death: a different view. *JAMA Internal Medicine* 2014;174:1215-6.

Truog RD, **Miller FG**. Defining death: the importance of scientific candor and transparency. *Intensive Care Medicine* 2014;40:885-7.

Truog RD, **Miller FG**. Changing the conversation about brain death. *American Journal of Bioethics* 2014;14(8):9-14.

Shah SK, Kasper K, **Miller FG**. A narrative review of the empirical evidence on public attitudes on brain death and vital organ transplantation: the need for better data to inform policy. *Journal of Medical Ethics* 2015;41:291-6.

Dickert NW, **Miller FG**. Learning from FAME: The need for sham controls in trials of stable coronary disease. *JACC: Cardiovascular Interventions* 2014;7:342-4.

Nayak RK, Pearson SD, **Miller FG**. Cost-related motivations for conducting research: participants should be informed, *JAMA* 2014;311:1491-2.

Kim S, **Miller FG**. Informed consent for pragmatic randomized clinical trials: the integrated consent model, *New England Journal* 2014;370:769-772.

**Miller FG**. The Stateville Penitentiary malaria experiments: a case study in retrospective ethical assessment, *Perspectives in Biology and Medicine* 2013;56:548-67.

Wendler D, **Miller FG**. The ethics of peer review in bioethics, *Journal of Medical Ethics* 2014;40:697-701.

Truog RD, **Miller FG**, Halpern S. The dead donor rule and the future of organ donation, *New England Journal* 2013;369:1287-9.

**Miller FG**. Clinical research before informed consent. *Kennedy Institute of Ethics Journal* 2014;24:141-57.

Brody H, Miller FG. The research/clinical practice distinction, learning health systems, and relationships. *Hastings Center Report* 2013;43(4):41-7.

Hull S, . . . **Miller FG**. A survey of patients' attitudes about the use of placebo treatments, *BMJ* 2013;346:f3757 doi: 10.1136/bmj.f3757.

**Miller FG**. Two philosophical deaths: Hume and Hitchens, *Perspectives in Biology and Medicine* 2013;56:251-58.

Brim R, **Miller FG**. The potential benefit of the placebo effect in sham-controlled trials: implications for risk/benefit assessment and informed consent, *Journal of Medical Ethics* 2013;39:703-7.

**Miller FG**, Joffe S. Phase 1 oncology trials and informed consent, *Journal of Medical Ethics* 2013;39:761-4.

**Miller FG**. The enduring legacy of sham-controlled trials of internal mammary artery ligation, *Progress in Cardiovascular Diseases* 2012;55:246-50.

Sommers R, **Miller FG**. Forgoing debriefing in deceptive research: is it ever ethical? *Ethics and Behavior* 2013;23:98-116.

Rhodes K, **Miller FG**. Simulated patient studies: an ethical analysis, *Milbank Quarterly* 2012;90:706-24.

**Miller FG**. Clinical equipoise and risk-benefit assessment, *Clinical Trials* 2012;9:621-7.

**Miller FG**. Homage to Henry Beecher, *Perspectives in Biology and Medicine* 2012;55:218-29.

Largent E, Grady C, **Miller FG**, Wertheimer A. Misconceptions about coercion and undue influence. *Bioethics* 2013;27:500-7.

Brody H, Colloca L, **Miller FG**. The placebo phenomenon: implications for the ethics of shared decision-making. *Journal of General Internal Medicine* 2012;27:739-42.

Joffe S, **Miller FG**. Equipoise: asking the right questions for clinical trial design. *Nature Reviews Clinical Oncology* 2012;9(4):230-5.

Sinnot-Armstrong W, **Miller FG**. Why killing by itself is not morally wrong. *Journal of Medical Ethics* 2013;39:3-7.

Brody H, **Miller FG**. From art to science: what has recent research taught us about the placebo effect in clinical practice? *JAMA* 2011;306:2612-3.

Largent E, Grady C, **Miller FG**, Wertheimer A. Money, coercion, and undue inducement: attitudes about payment to research participants, *IRB* 2012;34(1):1-8.

Wulff K, **Miller FG**, Pearson SD. Can coverage be rescinded when negative results threaten a popular procedure? The ongoing saga of vertebroplasty. *Health Affairs* 2011;30:2269-76..

**Miller FG**, Pearson SD. Linking insurance coverage for innovative invasive procedures with participation in clinical research, *JAMA* 2011;306:2024-5.

Shah SK, Truog RD, **Miller FG**. Death and legal fictions. *Journal of Medical Ethics* 2011;37:719-22.

Colloca L, **Miller FG**. The nocebo effect and its relevance for clinical practice. *Psychosomatic Medicine* 2011;73:598-603.

**Miller FG**. Dispensing with equipoise. *American Journal of the Medical Sciences* 2011;342:276-81.

**Miller FG**. Research and complicity: the case of Julius Hallervorden. *Journal of Medical Ethics* 2012;38:53-56.

**Miller FG**, Joffe S. Balancing access and evaluation in the approval of new cancer drugs. *JAMA* 2011;305:2345-6.

**Miller FG**, Wertheimer A. The fair transaction model of informed consent: an alternative to autonomous authorization, *Kennedy Institute of Ethics Journal* 2011;21:201-18.

Lie RK, **Miller FG**. What counts as reliable evidence for public health policy: the case of circumcision for preventing HIV infection. *BMC Medical Research Methodology* 2011;11:34.

**Miller FG**, Colloca L. The placebo phenomenon and medical ethics: rethinking the relationship between informed consent and risk-benefit assessment. *Theoretical Medicine and Bioethics* 2011;32:229-43.

**Miller FG**, Kallmes DF, Buchbinder R. Vertebroplasty and the placebo response. *Radiology* 2011;259:621-5.

Hrobjartsson A, Kaptchuk TJ, **Miller FG**. Placebo effect studies are susceptible to response biases and other types of biases. *Journal of Clinical Epidemiology* 2011;64:1223-9.

Colloca L, **Miller FG**. Role of expectation in health. *Current Opinion in Psychiatry* 2011;24:149-55.

Colloca L, **Miller FG**. How placebo responses are formed: a learning perspective. *Philosophical Transactions B* 2011;366:1859-69.



Colloca L, **Miller FG**. Harnessing the placebo effect: the need for translational research. *Philosophical Transactions B* 2011;366:1922-30.

**Miller FG**, Joffe S. Equipoise and the randomized clinical trial dilemma. *New England Journal of Medicine* 2011;364:476-80.

Largent E, Joffe S, **Miller FG**. Can research and care be ethically integrated? *Hastings Center Report* 2011;41(4):37-46.

Kaptchuk TJ, . . . **Miller FG**, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome, *PLoS One* 2010;5(12):e15591.

Litton P, **Miller FG**. What do physicians-investigators owe patients who participate in research? *JAMA* 2010;304:1491-2.

**Miller FG**, Colloca L. Semiotics and the placebo effect. *Perspectives in Biology and Medicine* 2010;53:509-16.

**Miller FG**, Kallmes DF. The case of vertebroplasty trials: promoting a culture of evidence-based procedural medicine. *Spine* 2010;35:2023-26.

Lev O, **Miller FG**, Emanuel EJ. The ethics of research on enhancement interventions. *Kennedy Institute of Ethics Journal* 2010;20:101-13.

Resnik DB, **Miller FG**. The ethics of sham surgery on research subjects with cognitive impairments that affect decision-making capacity. *Contemporary Clinical Trials* 2010;31:407-10.

**Miller FG**, Truog RD. Decapitation and the definition of death, *Journal of Medical Ethics* 2010;36:632-4 .

Shah S, **Miller FG**. Can we handle the truth? Legal fictions in the determination of death, *American Journal of Law and Medicine* 2010;36:540-585.

Tilburt JC, **Miller FG**, et al. Factors that influence practitioners' interpretation of evidence from alternative medicine trials: a factorial vignette experiment embedded in a national survey. *Medical Care* 2010;48:341-8.

**Miller FG**, Brody H. Understanding and harnessing the placebo effect: clearing away the underbrush. *Journal of Medicine and Philosophy* 2011;36:69-78.

Largent EA, Wendler D, Emanuel EJ, **Miller FG**. Is Emergency research without initial consent justified? The consent substitute model. *Archives of Internal Medicine* 2010;170:668-74.

Heyd D, **Miller FG**. Life plans: do they give meaning to our lives. *Monist* 2010;93:17-37.

Finniss DG, Kaptchuk TJ, **Miller F**, Benedetti F. Placebo effects: biological, clinical, and ethical advances, *Lancet* 2010;375:686-95.

Curlin FA, Rasinski KA, Kaptchuk TJ, Emanuel EJ, **Miller FG**, Tilburt JC. Religion, clinicians, and the integration of complementary and alternative medicine. *Journal of Complementary and Alternative Medicine* 2009;15:987-94.

**Miller FG**, Truog RD, Brock DW. The dead donor rule: can it withstand critical scrutiny? *Journal of Medicine and Philosophy* 2010;35:299-312.

**Miller FG**, Colloca L, Kaptchuk TJ. The placebo effect: illness and interpersonal healing, *Perspectives in Biology and Medicine* 2009;52:518-39.

Largent, **Miller FG**, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing, *Archives of Internal Medicine* 2009;169:1745-47.

**Miller FG**, Colloca L. The legitimacy of placebo treatments in clinical practice: evidence and ethics, *American Journal of Bioethics* 2009;9(12): 39-47.

**Miller FG**. Death and organ donation: back to the future. *Journal of Medical Ethics* 2009;35:616-20.

**Miller FG**, Joffe S. Limits to research risks. *Journal of Medical Ethics* 2009;35:445-449.

**Miller FG**, Truog RD. The incoherence of determining death by neurological criteria: Commentary on *Controversies in the Determination of Death*, A White Paper by the President's Council on Bioethics. *Kennedy Institutes of Ethics Journal* 2009;19:185-93.

**Miller FG**, Truog RD, Brock DW. Moral fictions and medical ethics. *Bioethics* 2010;24:453-60; reprinted in *Bioethics: An Anthology*, 3d edition, ed. by H. Khuse, U. Schuklenk, and P. Singer, John Wiley & Sons, Inc., 2016.

**Miller FG**. A planned death in the family. *Hastings Center Report* 2009;39(2):28-30.

Tilburt J, Curlin FA, Kaptchuk TJ, Clarridge B, Bolcic-Jankovic D, Emanuel EE, **Miller FG**. Alternative medicine research in clinical practice: A U.S. national survey. *Archives of Internal Medicine* 2009;169:670-77.

O'Neil C, **Miller FG**. When scientists deceive: applying the federal regulations. *Journal of Law, Medicine & Ethics* 2009;37:344-50.

Tilburt JC, Emanuel EJ, Kaptchuk TJ, Curlin FA, **Miller FG**. Prescribing “placebo treatments” in clinical practice: results of a national survey of U.S. internists and rheumatologists. *BMJ* 2008;337:a1938.

**Miller FG**, Joffe S. Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? *Clinical Trials* 2008;5:617-23.

Peppercorn J, . . . **Miller FG**, et al. Self-reported practices and attitudes of U.S. oncologists regarding off-protocol therapy. *Journal of Clinical Oncology* 2008;26:5994-6000.

Truog RD, **Miller FG**. The dead donor rule and organ donation. *New England Journal* 2008;359:674-5.

**Miller FG**, Gluck JP, Wendler D. Debriefing and accountability in deceptive research. *Kennedy Institute of Ethics Journal* 2008;18:235-51.

Tilburt JC, **Miller FG**, Emanuel EJ. Does the evidence make a difference in consumer behavior? Sales of supplements before and after publication of negative research results. *Journal of General Internal Medicine* 2008;23:1495-98.

**Miller FG**, Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. *Journal of the Royal Society of Medicine* 2008;101:222-25.

**Miller FG**. Collaborative research in bioethics, American Philosophical Association, *Newsletter on Medicine and Philosophy* 2008;7(2):17-20.

Brown AP, Wendler D, Camphausen KA, **Miller FG**, Citrin D. Performing non-diagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations, *Journal of Clinical Oncology* 2008;26:3987-94.

**Miller FG**, Kaptchuk. Deception of subjects in neuroscience: an ethical analysis, *Journal of Neuroscience* 2008;28:4841-43.

**Miller FG**, Truog RD. An apology for Socratic bioethics, *American Journal of Bioethics* 2008;8(7):3-7.

**Miller FG**, Truog RD. Rethinking the ethics of vital organ donations, *Hastings Center Report* 2008;38(6):38-46; reprinted in *ASBH Reader* Spring 2009.

Brendel D, **Miller FG**. A plea for pragmatism in clinical research ethics, *American Journal of Bioethics* 2008;8(4):24-31.

**Miller FG**. Research on medical records without informed consent, *Journal of Law, Medicine & Ethics* 2008;36:560-66.

Shalowitz D, **Miller FG**. Communicating the results of clinical research to participants: Attitudes, practices, and future directions. *PLoS Medicine* 2008;5(5):e91.

**Miller FG**, Emanuel EJ. Quality improvement research without informed consent, *New England Journal of Medicine* 2008;358:765-67.

Joffe S, **Miller FG**. Bench to bedside: mapping the moral terrain of clinical research, *Hastings Center Report* 2008;38(2):30-42.

**Miller FG**, Mello MM, Joffe S. Incidental findings in human subjects research: What do investigators owe research participants? *Journal of Law, Medicine & Ethics* 2008;36:271-79.

**Miller FG**, Pearson SD. Coverage with evidence development: ethical issues and policy implications. *Medical Care* 2008;46:746-57.

Henderson GE, . . . **Miller FG**, et al. Defining the therapeutic misconception: problems and prospects. *PLoS Medicine* 2007;4(11):e324.

Wertheimer A, **Miller FG**. Payment for research participation: A coercive offer? *Journal of Medical Ethics* 2008;34:389-92.

Horng S, **Miller FG**. Placebo controlled procedural trials for neurological conditions. *Neurotherapeutics* 2007;4:531-6.

**Miller FG**, Wendler D. Is it ethical to keep interim findings of randomized controlled trials confidential? *Journal of Medical Ethics* 2008;34:198-201.

Tilburt J, **Miller FG**. Responding to medical pluralism in practice: a principled ethical approach. *Journal of the American Board of Family Medicine* 2007;20:489-94..

Buchanan D, **Miller FG**, Wallerstein N. Ethical issues in community based participatory research: balancing rigorous research with community participation in intervention studies. *Progress in Community Health Partnerships* 2007;1.2:153-160.

**Miller FG**, Wertheimer A. Facing up to paternalism in research ethics. *Hastings Center Report* 2007;37(3):24-34.

Pearson SD, **Miller FG**, Emanuel EJ. Medicare's requirement for research participation as a condition for coverage: Is it ethical? *Journal of the American Medical Association* 2006;296:988-91.

Emanuel EJ, **Miller FG**. Money and distorted ethical judgments about research: Ethical assessment of the TeGenero TGN1412 trial. *American Journal of Bioethics* 2007;7(2):76-81.

**Miller FG**, Brody H. Clinical equipoise and the incoherence of research ethics. *Journal of Medicine and Philosophy* 2007;32:151-65.

**Miller FG**, Joffe S. Evaluating the therapeutic misconception. *Kennedy Institute of Ethics Journal* 2006;16:353-66.

Joffe S, **Miller FG**. Rethinking risk-benefit assessment for phase I cancer trials. *Journal of Clinical Oncology* 2006;24:2987-90.

Buchanan D, **Miller FG**. A public health perspective on research ethics. *Journal of Medical Ethics* 2006;32:729-33.

**Miller FG**, Kaptchuk TJ. Acupuncture trials and informed consent. *Journal of Medical Ethics* 2007;33:43-44.

Groopman L, **Miller FG**, Fins JJ. The patient's work. *Cambridge Quarterly of Healthcare Ethics* 2006;16:44-52. Reprinted in J. Pierce, G. Randels, eds., *Contemporary Bioethics: An Integrated Approach*, Oxford University Press, 2009.

**Miller FG**. Revisiting the Belmont Report: the ethical significance of the distinction between clinical research and medical care. American Philosophical Association, *Newsletter on Medicine and Philosophy* 2006;5(2):10-14.

Wendler D, **Miller FG**. Assessing research risks systematically: the net risks test. *Journal of Medical Ethics* 2007;33:481-6.

**Miller FG**, Wendler D. The relevance of empirical research in bioethics. *Schizophrenia Bulletin* 2006;32:37-41.

Shalowitz D, **Miller FG**. Disclosing individual results of clinical research: the implications of respect for participants. *JAMA* 2005;294:737-40.

**Miller FG**, Wendler D, Swartzman L. Deception in research on the placebo effect. *PLoS Medicine* 2005;2(9):e262.

**Miller FG**. Ethical issues in surgical research. *Thoracic Surgery Clinics* 2005;15:543-54.

Buchanan D, **Miller FG**. Justice and fairness in the Kennedy Krieger Institute lead paint study: the ethical justification for public health research on less expensive yet less effective interventions. *American Journal of Public Health* 2006;96:781-87.

MacKenzie R, **Miller FG**, Fins JJ. Justice and health care in rheumatic diseases. *HSS Journal*, 2005;1:58-63.

**Miller FG**, Brody H. Professional integrity in industry-sponsored clinical trials. *Academic Medicine* 2005;80:899-904.

**Miller FG**, Rosenstein DL. The nature and power of the placebo effect. *Journal of Clinical Epidemiology* 2006;59:331-35.

Litton P, **Miller FG**. A normative justification for distinguishing the ethics of clinical research from the ethics of medical care. *Journal of Law, Medicine & Ethics* 2005;33:566-74.

Brody H, **Miller FG**, Bogdan-Lovis E. Evidence-based medicine: watching out for its friends. *Perspectives in Biology and Medicine* 2005;48:570-84.

Buchanan D, **Miller FG**. Principles of early stopping of randomized trials for efficacy: a critique of equipoise and an alternative ethical framework. *Kennedy Institute of Ethics Journal* 2005;15:161-78.

**Miller FG**, Moreno JD. The state of research ethics: a tribute to John C. Fletcher. *Journal of Clinical Ethics* 2005;16:355-64.

Chen DT, . . . **Miller FG**, et al. Research with stored biological samples: What do research participants want? *Archives of Internal Medicine* 2005;165:652-55.

**Miller FG**. William James, faith, and the placebo effect. *Perspectives in Biology and Medicine* 2005;48:273-81.

Kaptchuk TJ, **Miller FG**. What is the best and most ethical model for the relationship between mainstream and alternative medicine: opposition, integration or pluralism? *Academic Medicine*, 2005;80:286-90.

**Miller FG**, Kaptchuk TJ. Sham procedures and the ethics of clinical trials. *Journal of the Royal Society of Medicine* 2004;97:576-78.

Raik BL, **Miller FG**, Fins JJ. Screening and cognitive impairment: ethics of forgoing mammography in older women. *Journal of the American Geriatrics Society* 2004;52:440-4.

**Miller FG**, Silverman HJ. The ethical relevance of the standard of care in the design of critical care trials. *American Journal of Respiratory and Critical Care Medicine*. 2004;169:562-64.

**Miller FG**, Emanuel EJ, Rosenstein DL, Straus SE. Ethical issues concerning research on complementary and alternative medicine. *JAMA* 2004;291:599-604.

Silverman HJ, **Miller FG**. Control group selection in critical care randomized controlled trials evaluating interventional strategies: an ethical assessment. *Critical Care Medicine* 2004;32:852-57.

**Miller FG, Wendler D.** Assessing the ethics of ethics research: a case study. *IRB*. 2004;26(2):9-12.

**Miller FG.** Research ethics and misguided moral intuition. *Journal of Law, Medicine & Ethics* 2004;32:111-116.

**Miller FG.** Sham surgery: an ethical analysis. *American Journal of Bioethics* 2003;3(4):41-8; reprinted in *Science and Engineering Ethics* 2004;10:157-66.

Wendler D, **Miller FG.** Deception in the pursuit of science. *Archives of Internal Medicine* 2004;164:597-600.

Brody H, **Miller FG.** The clinician-investigator: unavoidable but manageable tension. *Kennedy Institute of Ethics Journal*. 2003;13:329-46.

Eachempati SR, **Miller FG, Fins JJ.** The surgical intensivist as mediator of end-of-life issues in the care of critically ill patients. *Journal of American College of Surgeons*. 2003;197:847-53.

Rosenstein DL, **Miller FG.** Ethical considerations in psychopharmacological research involving decisionally impaired subjects. *Psychopharmacology*. 2003;171:92-7.

**Miller FG, Rosenstein DL.** The therapeutic orientation to clinical trials. *New England Journal of Medicine*. 2003;348:1383-86.

**Miller FG, Brody H.** A critique of clinical equipoise: Therapeutic misconception in the ethics of clinical trials. *Hastings Center Report*. 2003;33(3):19-28.

DiMichele D, **Miller FG, Fins JJ.** Gene therapy ethics and haemophilia: an inevitable therapeutic future? *Haemophilia*. 2003;9:145-52.

**Miller FG.** Clinical research with healthy volunteers: an ethical framework. *Journal of Investigative Medicine*. 2003;51 (Suppl)1:S2-5.

**Miller FG, Wendler D, Wilfond B.** When do the federal regulations allow placebo-controlled trials in children? *Journal of Pediatrics*. 2003;142:102-7.

Chen DT, **Miller FG, Rosenstein DL.** Ethical aspects of research into the etiology of autism. *Mental Retardation and Developmental Disabilities Research Reviews*. 2003;9:48-53.

Horng S, **Miller FG.** An ethical framework for the use of sham procedures in clinical trials. *Critical Care Medicine*. 2003;31(Suppl.):S126-S130.

Pace C, **Miller FG, Danis M.** Enrolling the uninsured in clinical trials: an ethical perspective. *Critical Care Medicine*. 2003;31(Suppl.):S121-S125.

Chen DT, **Miller FG**, Rosenstein DL. Clinical research and the physician-patient relationship. *Annals of Internal Medicine*. 2003;138:669-72.

Hornig S, **Miller FG**. Is placebo surgery unethical? *New England Journal of Medicine*. 2002; 347:137-9.

**Miller FG**, Rosenstein DL. Reporting of ethical issues in publications of medical research. *Lancet*. 2002;360:1326-28.

Chen DT, **Miller FG**, Rosenstein DL. Enrolling decisionally impaired adults in clinical research. *Medical Care*. 2002;40(supplement): V-20-V-29.

Charney DS, . . . **Miller FG**, et al. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. *Archives of General Psychiatry*. 2002;59:262-70.

**Miller FG**, Shorr AF. Ethical assessment of industry-sponsored clinical trials: a case analysis. *Chest*. 2002;121:1337-42.

**Miller FG**, Brody H. What makes placebo-controlled trials unethical? *The American Journal of Bioethics*. 2002;2(2):3-9.

**Miller FG**, Shorr AF. Unnecessary use of placebo controls: the case of asthma clinical trials. *Archives of Internal Medicine*. 2002;162:1673-7.

Emanuel EJ, **Miller FG**. The ethics of placebo-controlled trials—a middle ground. *New England Journal of Medicine*. 2001;345:915-9. Reprinted in Emanuel EJ et al. eds., *Ethical and Regulatory Aspects of Clinical Research: Readings and Commentaries*, Baltimore: The Johns Hopkins University Press, 2003.

Rosenstein DL, **Miller FG**, Rubinow DR. A curriculum for teaching psychiatric research bioethics. *Biological Psychiatry*. 2001;50:802-8.

**Miller FG**, Brody H. The internal morality of medicine: an evolutionary perspective. *Journal of Medicine and Philosophy*. 2001;26:581-99.

**Miller FG**, Grady C. The ethical challenge of infection-inducing challenge experiments. *Clinical Infectious Diseases*. 2001;33:1028-33.

Fins JJ, **Miller FG**. Enrolling decisionally incapacitated subjects in neuropsychiatric research. *CNS Spectrums*. 2000;5(10):32-42.

**Miller FG**. Placebo-controlled trials in psychiatric research: an ethical perspective. *Biological Psychiatry*. 2000;47:707-16. Revised version reprinted in *The Economics of Neuroscience*, September 2000.



**Miller FG**, Brody H, Chung KC. Cosmetic surgery and the internal morality of medicine. *Cambridge Quarterly of Healthcare Ethics*. 2000;9:353-64. Reprinted in Mappes TA and DeGrazia D, eds. *Biomedical Ethics*, 6<sup>th</sup> ed., Cambridge University Press, 2006; in B. Schone-Seifert and D. Talbot, eds. *Enhancement: Die ethische Debatte*, Mentis, 2009 (translated into German); and in J. Pierce, G. Randels, eds. *Contemporary Bioethics: An Integrated Approach*, Oxford University Press, 2009.

Fins JJ, **Miller FG**. Clinical pragmatism, ethics consultation and the elderly patient. *Clinics in Geriatric Medicine*. 2000;16:71-81.

**Miller FG**, Fins JJ, Snyder L. Assisted suicide compared with refusal of treatment: a valid distinction? *Annals of Internal Medicine*. 2000;132:470-5. Reprinted in Snyder L, Caplan AL, eds. *Assisted Suicide: Finding Common Ground*, Indiana University Press, 2002.

**Miller FG**, Rosenstein DL. Independent capacity assessment: a critique. *BioLaw*. September-October 1999;11(9-10):S:432-439.

**Miller FG**, Shorr AF. Advertising for clinical research. *IRB*. 1999;21(5):1-4.

Fins JJ, **Miller FG**, Acres CA, et al. End-of-life decision-making in the hospital: current practice and future prospects. *Journal of Pain and Symptom Management*. 1999;17:6-15.

**Miller FG**, Rosenstein DL, DeRenzo EG. Professional integrity in clinical research. *Journal of the American Medical Association*. 1998;280:1449-54.

**Miller FG**, Rosenstein DL. Protocol review within the context of a research program. *IRB*. 1998;20(4):7-10.

**Miller FG**, Caplan AL, Fletcher JC. Dealing with dolly: inside the national bioethics advisory commission. *Health Affairs*. 1998;17:264-7.

Brody H, **Miller FG**. The internal morality of medicine: explication and application to managed care. *Journal of Medicine and Philosophy*. 1998;23:384-410.

**Miller FG**, Meier DE. Voluntary death: a comparison of terminal dehydration and physician-assisted suicide. *Annals of Internal Medicine*. 1998;128:559-62.

**Miller FG**, Rosenstein DL. Psychiatric symptom-provoking studies: an ethical appraisal. *Biological Psychiatry*. 1997;42:403-9. Reprinted in Emanuel EJ et al. eds., *Ethical and Regulatory Aspects of Clinical Research: Readings and Commentaries*, Baltimore: The Johns Hopkins University Press, 2003.

Fins JJ, Bacchetta MD, **Miller FG**. Clinical pragmatism: a method of moral problem solving. *Kennedy Institute of Ethics Journal*. 1997;7:129-45. Reprinted in McGee G, ed. *Pragmatic Bioethics*, Vanderbilt University Press, 1999.

**Miller FG**. A communitarian approach to physician-assisted death. *Cambridge Quarterly of Healthcare Ethics*. 1997;6:78-87.

**Miller FG**, Brody H, Quill TE. Can physician-assisted suicide be regulated effectively? *Journal of Law, Medicine & Ethics*. 1996;24:225-32.

**Miller FG**, Fins JJ, Bacchetta MD. Clinical pragmatism: John Dewey and clinical ethics. *Journal of Contemporary Health Law and Policy*. 1996;13:27-51. Reprinted in Miller FG, ed. *Frontiers in Bioethics: Essays Dedicated to John C. Fletcher*, University Publishing Group, 2000.

**Miller FG**. Dedicatory Essay on John C. Fletcher. *Journal of Contemporary Health Law and Policy*. 1996;13:ix-xiv. Reprinted in Miller FG, ed., *Frontiers in Bioethics: Essays Dedicated to John C. Fletcher*, University Publishing Group, 2000.

**Miller FG**. Legalizing physician-assisted suicide by judicial decision: a critical appraisal. *BioLaw*. 1996;11(7-8):136-45..

**Miller FG**. Ethics for sale. American Philosophical Association, *Newsletter on Philosophy and Medicine*. 1996;96(1):84-5.

**Miller FG**, Fins JJ. A proposal to restructure hospital care for dying patients. *New England Journal of Medicine*. 1996;334:1740-2.

**Miller FG**, Brody H. Professional integrity and physician-assisted death. *Hastings Center Report*. 1995;25(3):8-17. Reprinted in *Monash Bioethics Review*, Vol. 15, January 1996.

**Miller FG**. The good death, virtue, and physician-assisted death. *Cambridge Quarterly of Healthcare Ethics*. 1995;4:92-7.

Fletcher JC, **Miller FG**, Caplan AL. Facing up to bioethical decisions. *Issues in Science and Technology*. 1994;11(1):75-80.

**Miller FG**, Quill TE, Brody H, et al. Regulating physician-assisted death. *New England Journal of Medicine*. 1994;331:119-23. Reprinted in Mappes TA, DeGrazia D, eds. *Biomedical Ethics* 5<sup>th</sup> ed., New York: McGraw-Hill, 2001.

**Miller FG**. Are patients in a persistent vegetative state alive or dead? American Philosophical Association, *Newsletter on Philosophy and Medicine*. 1994;94(1):126-7.

**Miller FG.** Freedom, power, and physician-assisted death. *American Philosophical Association, Newsletter on Philosophy and Medicine* 1993;92(2):75-77.

**Miller FG, Fletcher JC.** The case for legalized euthanasia. *Perspectives in Biology and Medicine*. 1993;36:159-76.

**Miller FG.** The concept of medically indicated treatment. *Journal of Medicine and Philosophy*. 1993;18:91-8.

**Miller FG.** Is active killing of patients always wrong? *Journal of Clinical Ethics*. 1991;2:130-2.

**Miller FG.** Restitution and punishment: A reply to Barnett. *Ethics* 1978;88:358-60. Reprinted in Boonin D, Oddie G, eds. *What's Wrong? Applied Ethicists and their Critics*, New York: Oxford University Press, 2005.

#### Commentaries and Editorials

**Miller FG.** Has physician-assisted death become the “good death? Hastings Center Bioethics Forum, posted 5/30/17.

**Miller FG.** Should bioethics respond to authoritarian populism? Hastings Center Bioethics Forum, posted 3/29/17.

Nair-Collins M, **Miller FG.** Is heart transplantation after circulatory death compatible with the dead donor rule? *Journal of Medical Ethics* 2016;42:319-20.

**Miller FG.** Treatment-resistant depression and physician-assisted death. *Journal of Medical Ethics* 2015;41:885-6.

**Miller FG, Truog RD.** Bioethics and the dogma of “brain death,” Hastings Center Bioethics Forum, posted 2/3/14.

**Miller FG.** Heart donation without the dead donor rule, *Annals of Thoracic Surgery* 2014;97:1133-4.

Wertheimer A, **Miller FG.** There are (STILL) no coercive offers. *Journal of Medical Ethics* 2014;40:592-3.

Gelinas L, **Miller FG.** Nudging, autonomy, and valid consent: context matters. *American Journal of Bioethics* 2013;13(6):12-13.

Largent E, **Miller FG, Joffe S.** A prescription for ethical learning. *Hastings Center Report Special Report* 2013;43 (1): S28-S29.

**Miller FG.** Is anything lost if we give up clinical equipoise? *Clinical Trials* 2012;9:632-3.

**Miller FG, Truog RD.** Going all the way: ethical clarity and ethical progress. *American Journal of Bioethics* 2012(6):10-11.

**Miller FG.** Ask the ethicist. Can a patient give valid consent to a phase 1 oncology trial? *Lahey Clinic Journal of Medical Ethics* 2012; 19(1):3.

**Miller FG.** Clarifying the nocebo effect and its ethical implications. *American Journal of Bioethics* 2012;12(3):30-31.

**Miller FG, Truog RD.** New hope for detecting consciousness in vegetative patients: ethical implications. *Bioethics Forum*, 11/29/11. [www.thehastingscenter.org/Bioethicsforum](http://www.thehastingscenter.org/Bioethicsforum).

**Miller FG.** On authorship. *American Journal of Bioethics* 2011;11(10):32-3.

Kallmes DF, Buchbinder R, **Miller FG.** Randomised controlled trials using invasive control interventions should be included in Cochrane Reviews [editorial]. *The Cochrane Library* 2011 (6 July).

**Miller FG, Joffe S.** Science, ethics, and politics in drug regulation: the case of Avastin. *Bioethics Forum*, 7/8/11. [www.thehastingscenter.org/Bioethicsforum](http://www.thehastingscenter.org/Bioethicsforum).

**Miller FG.** Plagiarism and bioethics. *Bioethics Forum*, 2/22/11. [www.thehastingscenter.org/Bioethicsforum](http://www.thehastingscenter.org/Bioethicsforum).

Truog RD, **Miller FG.** Brain perfusion scans to diagnose brain death: more than meets the eye. *Pediatric and Critical Care Medicine* 2010;11:527-8.

Truog RD, **Miller FG.** Counterpoint: are donors after circulatory death really dead, and does it matter? No and not really. *Chest* 2010;138:16-18.

**Miller FG.** Striking the right balance in research ethics and regulation. *American Journal of bioethics* 2010 (8);10:65.

**Miller FG, Truog RD.** The incoherence of determining death by neurological criteria: reply to John Lizza. *Kennedy Institute of Ethics Journal* 2009;19:397-99.

**Miller FG.** The rationale for placebo-controlled trials: methodology and policy considerations. *American Journal of Bioethics* 2009;9(9):49-50.

**Miller FG, Wendler D.** The ethics of sham invasive intervention trials. *Clinical Trials* 2009;6:401-02.

**Miller FG.** The randomized controlled trial as a demonstration project: an ethical perspective. *American Journal of Psychiatry* 2009;743-45.

**Miller FG.** Muddling through? A commentary on *Controversies in the Determination of Death*. *Bioethics Forum* 1/22/09, [www.thehastingscenter.org/Bioethicsforum](http://www.thehastingscenter.org/Bioethicsforum).

Shalowitz D, **Miller FG.** The Search for clarity in communicating study results to research participants, *Journal of Medical Ethics* 2008;34:e17.

**Miller FG.** Equipoise and the ethics of clinical research revisited. *American Journal of Bioethics* 2006;6(4):59-61.

**Miller FG, Rosenstien DL.** Response to commentary. *Journal of Clinical Epidemiology* 2006;59:339.

**Miller FG, Moreno JD.** Informed consent and the ethics of clinical research: reply to commentaries. *Journal of Clinical Ethics* 2005;16:376-79.

**Miller FG.** The case for a code of ethics for bioethicists: some reasons for skepticism. *American Journal of Bioethics* 2005; 5(5):50-52.

**Miller FG, Brody H.** Enhancement technologies and professional integrity. *American Journal of Bioethics* 2005; 5(3):15-17.

**Miller FG.** Does research ethics rest on a mistake? *American Journal of Bioethics*. 2005;5(1):34-36.

Schechter AN, **Miller FG.** To publish or not to publish? *Journal of Laboratory and Clinical Medicine*. 2005;145:9-11.

**Miller FG.** Ethical issues in research with healthy volunteers: risk-benefit assessment. *Clinical Pharmacology and Therapeutics*. 2003;74:513-5.

**Miller FG.** Ethical significance of ethics-related empirical research. *Journal of the National Cancer Institute*. 2002;94:1821-22.

**Miller FG, Fins JJ.** Protecting vulnerable research subjects without unduly constraining neuropsychiatric research. *Archives of General Psychiatry*. 1999;56:701-02.

Fins JJ, **Miller FG, Bacchetta MD.** Clinical pragmatism: bridging theory and practice. *Kennedy Institute of Ethics Journal*. 1998;8:37-42.

**Miller FG.** Commentary: professional integrity in the home. *Journal of Pain and Symptom Management*. 1998;15:138-9.

**Miller FG.** Comments on second report of the Attorney General's Research Working Group on Research with Decisionally Impaired Individuals. *Journal of Health Care Law & Policy.* 1998;1:193-201.

Fins JJ, **Miller FG.** The call of the sirens: navigating the ethics of medication-free research in schizophrenia. *Archives of General Psychiatry.* 1997;54:415-6.

### Books

Quill TE, **Miller FG,** eds. *Palliative Care and Ethics.* New York: Oxford University Press, 2014.

**Miller FG,** Colloca L, Crouch RA, Kaptchuk TJ, eds. *The Placebo: A Reader.* Baltimore: Johns Hopkins University Press, 2013.

**Miller FG.** *The Ethical Challenges of Human Research: Selected Essays.* New York: Oxford University Press, 2012.

**Miller FG,** Truog RD. *Death, Dying, and Organ Donation: Reconstructing Medical Ethics at the End of Life.* New York: Oxford University Press, 2012.

**Miller FG,** Wertheimer A, eds. *The Ethics of Consent: Theory and Practice.* New York: Oxford University Press, 2010.

Emanuel EJ, Crouch RA, Grady C, Lie R, **Miller FG,** Wendler D, eds. *The Oxford Textbook of Clinical Research Ethics,* New York: Oxford University Press, 2008.

**Miller FG,** Fletcher JC, Humber JH, eds. *The Nature and Prospect of Bioethics: Interdisciplinary Perspectives.* Humana Press, 2003.

**Miller FG,** ed. *Frontiers in Bioethics: Essays Dedicated to John C. Fletcher.* University Publishing Group, 2000.

Fletcher JC, Lombardo PA, Marshall MF, **Miller FG,** eds. *Introduction to Clinical Ethics* 2<sup>nd</sup> edition, University Publishing Group, 1997.

### Book Chapters

Quill, TE, **Miller FG.** Physician-Assisted Death. In Quill TE, Miller FG, eds. *Palliative Care and Ethics.* New York: Oxford University Press, 2014.

Colloca L, **Miller FG.** Placebo and nocebo: ethical challenges and solutions. In Colloca L, Flaten MA, Meissner, eds. *Placebo and Pain: from Bench to Bedside.* Elsevier, 2013.

**Miller FG.** Situating research ethics: revisiting Beecher and Jonas. In Miller FG, *The Ethical Challenges of Human Research*. Oxford University Press, 2012.

Hrobjartsson A, **Miller FG.** Placebo control groups in non-pharmacological randomized trials. In Boutron I, Ravaud P, Moher D, eds. *Randomized Clinical Trials of Nonpharmacologic Treatments*. Taylor and Francis, 2012.

**Miller FG.** Consent to Clinical Research. In Miller FG, Wertheimer A, eds. *The Ethics of Consent: Theory and Practice*. New York: Oxford University Press, 2010.

**Miller FG,** Wertheimer A. Preface to a theory of consent transactions: beyond valid consent. In Miller FG, Wertheimer A, eds.. *The Ethics of Consent: Theory and Practice*. New York: Oxford University Press, 2010.

Rosenstein DL, **Miller FG.** Research ethics in psycho-oncology. In Holland J, ed. *Psycho-oncology*, 2<sup>nd</sup> ed. Oxford University Press, 2010.

**Miller FG,** Rosenstein DL. The ethics of psychiatric research. In: Bloch S and Green S. *Psychiatric Ethics*, 4th ed. Oxford University Press, 2009.

**Miller FG.** The ethics of placebo-controlled trials. In: Emanuel EJ, Crouch RA, Grady C, Lie R, Miller FG, Wendler D, eds. *The Oxford Textbook of Clinical Research Ethics*, 2008.

**Miller FG.** Ethical issues in recruiting research subjects. In: Emanuel EJ, Crouch RA, Grady C, Lie R, Miller FG, Wendler D, eds. *The Oxford Textbook of Clinical Research Ethics*, 2008.

**Miller FG,** Rosenstein DL. Challenge experiments. In: Emanuel EJ, Crouch RA, Grady C, Lie R, Miller FG, Wendler D, eds. *The Oxford Textbook of Clinical Research Ethics*, 2008.

Wendler D, **Miller FG.** Deception. In: Emanuel EJ, Crouch RA, Grady C, Lie R, Miller FG, Wendler D, eds. *The Oxford Textbook of Clinical Research Ethics*, 2008.

Wendler D, **Miller FG.** Risk-benefit analysis and the net risks test. In: Emanuel EJ, Crouch RA, Grady C, Lie R, Miller FG, Wendler D, eds. *The Oxford Textbook of Clinical Research Ethics*, 2008.

Jonsen A, **Miller FG.** Research with Healthy Volunteers. In: Emanuel EJ, Crouch RA, Grady C, Lie R, Miller FG, Wendler D, eds. *The Oxford Textbook of Clinical Research Ethics*, 2008.

Rosenstein DL, **Miller FG.** Research with Cognitively Impaired Subjects. In: Emanuel EJ, Crouch RA, Grady C, Lie R, Miller FG, Wendler D, eds. *The Oxford Textbook of Clinical Research Ethics*, 2008.

Buchanan D and **Miller FG**. Justice in human subjects research. In: Rhodes R, Francis L, Silvers A, eds. *The Blackwell Guide to Medical Ethics*, Blackwell Publishing, 2006.

**Miller FG**, Fins JJ. Protecting human subjects in brain research: a pragmatic perspective. In: Illes J, ed. *Neuroethics*, Oxford University Press, 2006.

Rosenstein DL, **Miller FG**. Ethical Issues. In: Levinson JL, ed. *Textbook of Psychosomatic Medicine*, 2<sup>nd</sup> edition. The American Psychiatric Press, 2011.

Fletcher JC, **Miller FG**, Spencer EM. Clinical ethics: history, content, and resources. In Fletcher JC, ed. *Introduction to Clinical Ethics*, 2nd edition, University Publishing Group, 1997.

**Miller FG**, Fletcher JC, Fins JJ. Clinical pragmatism: a case method of moral problem solving. In Fletcher JC, *Introduction to Clinical Ethics*, 2nd edition, University Publishing Group, 1997.

Fletcher JC, **Miller FG**. The promise and perils of public bioethics. In Vanderpool HY, ed. *The Ethics of Research Involving Human Subjects: Facing the 21st Century*, University Publishing Group, 1996.

**Miller FG**, Fletcher JC. Physician-assisted suicide and active euthanasia. In Humber JM, Almeder RF, Kasting GA, eds. *Physician-Assisted Death*, Humana Press, 1994.

#### Edited Journal Volumes

**Miller FG**, Fins JJ. Special Issue on Disciplines of Bioethics: Personal Perspectives. *Perspectives in Biology and Medicine* 2017;60(1).

**Miller FG**, Lantos J. Henry Beecher and the Ethics of Clinical Research. *Perspectives in Biology and Medicine* 2016;59(1).

**Miller FG**, Veatch RM. Symposium on Equipoise and the Ethics of Clinical Trials. *Journal of Medicine and Philosophy* 2007;32(2).

Veatch RM, **Miller FG**. The Internal Morality of Medicine. *Journal of Medicine and Philosophy* 2001;26(6).

#### Book Reviews

**Miller FG**. Review essay. Facing Death. *Perspectives in Biology and Medicine* 2016;59:581-6.



**Miller FG.** Review of *Rational Suicide, Irrational Laws*, by Susan Steffan. *American Journal of Psychiatry* 2016;173:736-7.

**Miller FG.** Review essay. *Brilliant Green: The Surprising History and Science of Plant Intelligence*, by Stefano Mancuso and Alessandro Viola, *Perspectives in Biology and Medicine* 2014;57:569-74.

**Miller FG.** Review of *The Woman Who Decided to Die: Challenges and Choices at the Edges of Medicine*, by Ronald Munson, *New England Journal of Medicine*. 2009;360:2585.

**Miller FG.** Elegy for Iris: the ethics of narrative. American Philosophical Association, *Newsletter on Philosophy and Medicine*. 1999;99 (1):107-09.

**Miller FG.** Review of *A Time to Die: The Place of Physician Assistance*, by Charles F. McKhann, *New England Journal of Medicine*. 1998;339:1562-63.

**Miller FG.** Review of *Physician Assisted Suicide* edited by Robert F. Weir. *New England Journal of Medicine*. 1997;337:943.

**Miller FG.** Review of *A Chosen Death* by Lonny Shavelson. *New England Journal of Medicine*. 1996;334:205.

**Miller FG.** Review of *No Longer Patient* by Susan Sherwin. The American Philosophical Association, *Newsletter on Philosophy and Medicine*, 1992;91(2).88-90.

**Miller FG.** Review of *Real Presences* by George Steiner. *Journal of Speculative Philosophy* 1990;4.176-80.

#### Letters to the Editor

Truog RD, **Miller FG.** “Brain death” is a useful fiction. *Critical Care Medicine* 2012;40:1353-4.

**Miller FG,** Kaptchuk TJ. Acupuncture for chronic pain. *New England Journal* 2010;363:1776.

**Miller FG,** Truog RD. Controversies about brain death. *JAMA* 2009;302:380.

**Miller FG.** Deceptive research. *Archives of General Psychiatry* 2008;65:1225-6.

**Miller FG.** Therapeutic Misconception. *Hastings Center Report* 2008;38(2):6.

Snyder DJ, **Miller FG,** Rosenstein DL. Solicitation of deceased and living organ donors. *New England Journal of Medicine* 2007;356:2427-9.

**Miller FG.** Financial relationships of Institutional Review Board members. *New England Journal of Medicine* 2007;356:965.

**Miller FG, Kaptchuk TJ.** Puzzling questions about acupuncture. *Annals of Internal Medicine* (electronic letter), July 11, 2006.

Shalowitz DI, **Miller FG.** Implications of disclosing individual results of clinical research. *JAMA* 2006;295:37-38.

Brody H, **Miller FG.** Academic-industrial relationships. *New England Journal of Medicine* 2005;353:2721.

**Miller FG, Wendler D.** Direct-to-consumer advertising and physician prescribing. *JAMA* 2005;294:678.

**Miller FG, Wendler D.** Placebo research and the spirit of informed consent. *Psychosomatic Medicine* 2005;67:678.

**Miller FG.** The debate over placebo-controlled trials. *PLoS Medicine* 2005;2:565-66.

**Miller FG, Lie RK.** Acupuncture research and informed consent. *Pain* 2004;112:411.

**Miller FG.** Painful deception. *Science* 2004;304:1109-10.

**Miller FG, Emanuel EJ, Rosenstein DL, Straus SE.** Ethical issues in research in complementary and alternative medicine—reply. *JAMA* 2004;291:2193-94.

**Miller FG.** End-of-life care for patients with dementia. *New England Journal of Medicine* 2004;350:733.

**Miller FG, Brody H.** Clinical equipoise: more uncertainty. *Hastings Center Report* 2003; 33(6):4-5.

**Miller FG, Brody H.** Clinical equipoise and the therapeutic misconception. *Hastings Center Report* 2003;33(5):4-7.

**Miller FG, Shorr AF.** Continued need for placebo in many cases, even when there is effective therapy. *Archives of Internal Medicine.* 2003;163:373.

**Miller FG, Brody H.** Response to commentaries. *American Journal of Bioethics* 2002;2(2).

**Miller FG.** Treatment of acute migraine. *Lancet.* 2002;359:802.

**Miller FG, Shorr AF.** Salmeterol and inhaled corticosteroids in patients with persistent asthma. *JAMA.* 2001;286:3075-6.

**Miller FG.** Is the placebo powerless? *New England Journal of Medicine* 2001;345:1277.

**Miller FG, Rosenstein DL.** Does rapid tryptophan depletion induce depressive relapse? *Neuropsychopharmacology.* 2001;25:614-5.

**Miller FG.** To protect those who serve. *New England Journal of Medicine.* 2001;344:1018-9.

**Miller FG, Pickar D, Rosenstein DL.** Addressing ethical issues in the psychiatric research literature. *Archives of General Psychiatry.* 1999;56:763-4.

Shorr AF, **Miller FG.** Psychotherapy for depression in diabetes. *Annals of Internal Medicine.* 1999;131:70.

**Miller FG.** An open future. *Hastings Center Report.* 1997;27(5):5.

**Miller FG.** Re: The ethics of death-hastening or death-causing palliative analgesic administration. *Journal of Pain and Symptom Management.* 1997;14:2.

**Miller FG.** Re: Female genital surgeries. *Hastings Center Report.*,. 1997;27(2):4.

**Miller FG.** Euthanasia and physician-assisted suicide in the Netherlands. *New England Journal of Medicine.* 1997;336:1386.

Fins JJ, **Miller FG.** Hanging a morphine drips. *Journal of Palliative Care.* 1997;13:52.

**Miller FG, Fletcher JC.** Criticism or caricature. *Hastings Center Report.* 1995;25(2):3.

Caplan AL, **Miller FG, Fletcher JC.** Bioethics in Washington: yes, but how? *JAMA* 1994;272:1323.

**Miller FG.** Euthanasia: still open for debate. *Journal of Clinical Ethics.* 1992;3:247-8.

**Miller FG.** Importance of understanding suffering for clinical ethics. *Journal of Clinical Ethics.* 1991;2:290-1.

**Miller FG.** Ethics is everybody's concern. *Journal of Clinical Ethics.* 1990;1:326-7.

#### Other Publications

Fried, C. *Medical Experimentation, New Edition.* Edited, with an introduction by **F.G. Miller** and A. Wertheimer. Oxford University Press, 2016.

**Miller FG**, Grady C. In Memoriam: Alan Wertheimer. *Hastings Center Report* 2015; 45(2):6.

Childress JF, **Miller FG**. In Memoriam: John C. Fletcher. *Hastings Center Report*. 2004;34(4):49.

**Miller FG**. John Fletcher, In Memorial. American Philosophical Association, Newsletter on Philosophy and Medicine. 2004;4(1).

## PRESENTATIONS

Seminar on Research Ethics, Division of Medical Ethics, Weill Cornell Medical College, February 15, 2017.

Panel on consent and internet research, Ethics Grand Rounds, National Institutes of Health, December 7, 2016.

“Placebos in research and practice,” University of Marburg, seminar for medical students, Kleinwalsertal, Austria, September 28, 2015.

“On Collaboration,” The Frontiers of Bioethics: a conference honoring the career and collaborations of Franklin G. Miller, National Institutes of Health, May 29, 2015.

“Comparative Effectiveness Trials and Informed Consent,” Workshop, “Risk-adapted approaches to regulating health research: ethical challenges,” Kings College London, April 20, 2015.

“Determination of Death and Organ Transplantation,” Department of Bioethics, NIH, Fellows seminar, April 15, 2015; November 16, 2015; April 12, 2017.

“Comparative Effectiveness Trials and Informed Consent,” NIH Human Subjects Research Course, October 29, 2014.

“Phase I oncology trials and informed consent,” Brocher Foundation symposium on “Recent developments in phase 1 oncology trials,” Hermance, Switzerland, July 15, 2014.

“Infection challenge studies: an ethical perspective, NIAID/FDA Workshop on Dengue human infection model, Rockville, MD, April 3, 2014.

“Crisis in the ethics of vital organ donation,” George Washington University Ethics Committee Retreat, March 26, 2014.

“Placebos and the ethics of therapeutic communication,” Symposium on Placebo Effects in Guidelines, Practice, and Patient Choice, Boston, December 10, 2013.

“Research without consent: the case of ‘mystery shopper’ studies,” panel on the Ethics of Research without Consent, Advancing Ethical Research Conference, Public Responsibility in Medicine and Research, Boston, November 8, 2013.

“Ethics of single-blind trials in biomedicine,” symposium on “When Less Information is better: blinding as a solution to institutional corruption,” The Edmond J. Safra Center for Ethics at Harvard, November 1, 2013.

“Crisis in the ethics of vital organ donation: Where do we go from here?” Workshop on The importance of being dead—The dead donor rule and ethics of transplantation medicine, Center for Interdisciplinary Research, University of Bielefeld, Bielefeld Germany, September 14, 2013.

“Deception and research: ethics and regulation,” NHGRI IRB retreat, NIH Clinical Center, June 13, 2013.

“Placebo-controlled trials without informed consent: What were they thinking?” Panel on RCTs and Informed Consent, Princeton University, April 25, 2013.

“Limits to Research Risks,” George Mason University, March 7, 2014; April 5, 2013.

“Abandoning the Dead Donor Rule,” Society for Thoracic Surgeons annual meeting, Los Angeles, CA, January 29, 2013.

“Simulated Patient Studies,” Division of Medical Ethics, Cornell Medical School, January 17, 2013.

“Limits to risks in research with healthy volunteers,” Advanced Research Ethics workshop, PRIM&R annual meeting, San Diego, CA, 12/3/12.

“Placebo-controlled trials before informed consent: What were they thinking?” Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard University, October 25, 2012.

“Doctors must not Kill,” panel presentation at annual meeting of American Society for Bioethics and the Humanities, Washington, D.C., October 19, 2012.

“Sham-controlled trials: an ethical perspective,” Gastroenterology and Urological Devices Panel of the FDA Medical Devices Advisory Committee, Gaithersburg, MD, May 10, 2012.

“Data Safety and Monitoring Boards: An Ethical Perspective,” “Limits to Risks in Research with Healthy Volunteers,” “Therapeutic Orientation to Clinical Trials,” Ewha-NIH Intensive Course in Human Subject Research Ethics, Seoul, South Korea, March 19-22, 2012.

“Research without consent: the case of mystery shopping studies,” conference on Rethinking the Ethics of Clinical Research, Duke University, Durham, North Carolina, February 24, 2012.

“Legitimacy of Placebo Treatments,” Placebo Conference, sponsored by Samueli Institute, Bethesda, Maryland, January 20, 2012.

“Placebo treatments in clinical practice: ethical issues,” Healing and Placebo panel discussion, Embassy of Italy, January 20, 2012.

“Dispensing with equipoise,” Advanced Research Ethics, PRIM&R, National Harbor, MD, December 1, 2011.

“Sham-controlled trials—ethical and policy considerations,” conference on Device development in obesity, sponsored by FDA and Massachusetts General Hospital, Bethesda, Maryland, October 17, 2011.

“Organ Donation Without the Dead Donor Rule,” University of Marburg, seminar on death, organ donation, and ethics, Kleinwalsertal, Austria, October 3, 2011.

“The Therapeutic Misconception and Informed Consent,” Grand Rounds, Clinical Center, NIH, August 31, 2011.

“Therapeutic Orientation to Clinical Trials,” First Annual Biomedical Ethics Lecture, University of Rochester Medical Center, Rochester, New York, June 21, 2011.

“Limits to research risks,” National Institute of Environmental Health Sciences, Research Triangle, North Carolina, May 25, 2011.

“Drug evaluation: public policy and research ethics,” Office of Oncology Drug Products, FDA, April 29, 2011.

“Deception and research: ethics and regulation,” Department of Veterans Affairs, Central IRB, Washington, DC, February 24, 2011.

“Vertebroplasty and the Placebo Response,” Radiological Society of North America annual meeting, Chicago, December 1, 2010.

“Beyond Superiority to Placebo: The Legitimacy of Placebo Efficacy?” Integrative Medicine Research Lecture series, National Center for Complementary and Alternative Medicine, NIH, November 8, 2010.

“Dispensing with Equipoise,” Pitts Memorial Lectureship, Medical University of South Carolina, Charleston, SC, October 30, 2010.

“Coverage with Evidence Development: Ethical Issues,” panel on research and practice, American Society for Bioethics and the Humanities, annual meeting, San Diego, CA, October 23, 2010.

“Deception in Research: Ethics and Regulation,” Secretary’s Advisory Committee on Human Research Protections, Washington, D.C., October 20, 2010.

“Placebo Treatments in Clinical Practice: Ethical Issues,” Grand Rounds, Comprehensive Cancer Support Program, University of North Carolina, September 13, 2010.

“The Ethics of Placebo-Controlled Trials,” Rush University Medical Center, Chicago, June 16, 2010.

“Therapeutic orientation to clinical trials,” Grand Rounds, Children’s Hospital of Philadelphia, May 12, 2010.

“Organ Donation without the Dead Donor Rule,” American Philosophical Association, central division meeting, Committee for Medicine and Philosophy, Chicago, February 20, 2010.

“Risks and Placebo Controls,” World Medical Association expert conference on the ethics of placebo controls in clinical trials, Sao Paulo, Brazil, February 1, 2010.

“Therapeutic Orientation to Clinical Trials,” Clinical Research Ethics Seminar, University of Texas Southwestern, December 8, 2009.

“Organ Donation without the Dead Donor Rule,” Ethics Grand Rounds, University of Texas Southwestern, December 8, 2009.

“Placebo Treatments in Clinical Practice: Ethical Issues,” at a conference on placebo interventions in medical practice sponsored by the Institute for Biomedical Ethics, University of Zurich, Zurich, Switzerland, November 18, 2009.

“Informed Consent and Therapeutic Misconception,” International Association of Law and Mental Health, New York City, June 30, 2009.

“Placebo treatments in clinical practice: ethical issues,” George Washington University Medical School, April 8, 2009.

“Research Ethics at the NIH,” Global Alliance of Biomedical Ethics Centers Project, Tokyo, Japan, March 13, 2009.

“Standard of Care and the Ethics of Study Design,” IMPAACT Leadership Retreat, Division of AIDS, NIAID, NIH, December 12, 2008.

“Facing up to deception in placebo research,” The Placebo Effect: Satellite symposium of the X11 World Congress on Pain, Copenhagen, August 15, 2008.

“Placebo treatments in clinical practice: ethical issues,” X11 World Congress on Pain, Glasgow, August 18, 2008.

“Ethical Issues in CAM Clinical Trials,” National Center for Complementary and Alternative Medicine, Grantsmanship Workshop, Rockville, MD, June 5, 2008.

“Epidemiological and Health Services Research without Consent,” Medical Ethics Seminar, Division of Medical Ethics, Department of Public Health, Weill Medical College of Cornell University, March 6, 2008.

“Therapeutic Orientation to Clinical Trials,” Advanced Research Ethics, PRIM&R Annual HRPP Conference, Boston, MA 12/1/07.

“Therapeutic Orientation to Clinical Trials,” NIH Human Subjects Research Ethics Course, October 3, 2007.

“Don’t Look, Don’t Tell, Why Not?” conference on Managing Incidental Findings in Human Subjects Research, University of Minnesota, May 1, 2007.

“Deception, Respect for Persons, and Informed Consent,” retreat for Institutional Review Board of the Intramural Research Program, National Human Genome Research Institute, March 19, 2007.

“Coverage Conditional on Research: An Ethical Perspective,” workshop on Ethical Considerations for Post-marketing Evaluations of Pharmaceuticals,” sponsored by Health Canada, The Canadian Institutes of Health Research, and The Manitoba Centre for Health Policy, Toronto, Canada, March 5, 2007.

“Deception, Respect for Persons, and Informed Consent,” RAND Corporation, conference on Ethical Principles in Social-Behavioral Research on Terrorism, Arlington, VA January 10, 2007.

“Against Clinical Equipoise,” PRIM&R Annual HRPP Conference, Washington, DC, November 16, 2006.

“Therapeutic Orientation to Clinical Trials,” Ethics Grand Rounds, Dana-Farber Cancer Institute, Harvard School of Medicine, October 16, 2006.

“Facing up to Paternalism in Research Ethics,” Division of Medical Ethics, Harvard Medical School, October 16, 2006.

“Data Safety and Monitoring Boards: An Ethical Perspective,” Indo-U.S. Workshop on Bioethics in Clinical Research,” New Delhi, India, June 21, 2006.



“The Therapeutic Misconception and Informed Consent,” Indo-U.S. Workshop on Bioethics in Clinical Research,” New Delhi, India, June 22, 2006.

“Evaluating the Therapeutic Misconception,” panel on Therapeutic Misconception in Clinical Research, American Psychiatric Association, May 22, 2006.

“Deception in Clinical Research: the Challenge to Informed Consent,” Medical Ethics Seminar, Division of Medical Ethics, Department of Public Health, Weill Medical College of Cornell University, May 11, 2006.

“Therapeutic Orientation to Clinical Trials,” University of Marburg Comprehensive Cancer Center, March 15, 2006.

“Distinguishing the Ethics of Clinical Research from the Ethics of Medical Care,” Panel on The Belmont Report, American Philosophical Association, December 29, 2005.

“Ethics of Placebo-Controlled Trials,” Human Subjects Research Course, National Institutes of Health, October 19, 2011; October 5, 2010; October 28, 2009; October 15, 2008; October 10, 2007; October 11, 2006; November 2, 2005.

“Distinguishing the Ethics of Clinical Research from the Ethics of Medical Care,” Panel on The Belmont Report, American Society for Bioethics and the Humanities, October 22, 2005.

“The Therapeutic Orientation to Clinical Trials,” University of Maryland School of Medicine, June 16, 2005.

“Deception in Clinical Research on the Placebo Effect,” Osher Institute, Harvard Medical School, May 24, 2005.

“Deception in Clinical Research: The Case of Experiments to Investigate the Placebo Effect,” University of New Mexico, April 14, 2005.

“Data Safety and Monitoring Boards: An Ethical Perspective,” AMANET/NIH Advanced Ethics Workshop, Zanzibar, Tanzania, December 1, 2004.

“The Ethics of Medical Research with Human Subjects,” Cedar Lane Unitarian Church, Chevy Chase, Maryland, October 17, 2004.

“The Ethics of Placebo-Controlled Trials,” Quorum IRB retreat, Seattle, Washington (by telephone), October 2, 2004.

“Professional Integrity in Industry-Sponsored Trials,” Aventis Editorial Forum, Bridgewater, New Jersey, October 1, 2004.

“Ethical Framework for Randomized Controlled Trials,” National Institute of Aging conference, “From Bench to Bedside: Estrogen as a Case Study,” September 29, 2004.

“Deception in Placebo Research,” Human Subjects Research Ethics Board Retreat, University of Western Ontario, June 8, 2004.

The Ethics of Placebo Surgery,” Society for Clinical Trials Annual Meeting, New Orleans, May 26, 2004.

“William James and Medical Ethics,” Bioethics Seminar, Division of Medical Ethics, Cornell University Medical College, March 25, 2004.

“Is ‘Faith Healing’ Compatible with Scientific Medicine? The Ethics of Placebo Therapy,” Placebo Working Group, Osher Institute, Harvard Medical School, December 18, 2003.

“Kant and Bioethics,” Bioethics Seminar, Division of Medical Ethics, Cornell University Medical College, December 12/4/03.

“The Therapeutic Orientation to Clinical Trials,” at The Ethical Conduct of Clinical Research Involving Critically Ill Subjects in North America Conference, American Thoracic Society, November 21, 2003.

“Commentary on a Complex Trial Design,” Inter-Institute Bioethics Interest Group, National Institutes of Health, November 3, 2003.

“Professional Integrity in Clinical Research,” Key Plenary Conference, XXI Biomedical Research National Congress, Monterrey, Mexico, October 23, 2003.

“Placebo-controlled Trials in Children: Ethical and Regulatory Considerations,” North American Cystic Fibrosis Conference, Anaheim, CA, October 16, 2003.

“The Ethics of Placebo Surgery,” Conference on “Placebo—Its Action and Place in Health Research Today,” The Medical University of Warsaw, Warsaw, Poland, April 13, 2003.

“The Ethics of Sham Surgery,” Alumni Reunion, Clinical Research Training Program, National Institutes of Health, October 5, 2002.

“The Ethics of Placebo-controlled trials,” Collegium Internationale Neuro-Psychopharmacologicum, Montreal, Canada, June 25, 2002.

“Assessing Decisionmaking Capacity in Psychiatric Research,” Society of Biological Psychiatry, Philadelphia, PA, May 16, 2002.

“Clinical Research with Healthy Volunteers,” American Federation for Medical Research,” Baltimore, MD, April 13, 2002.

“The Ethics of Placebo-Controlled Trials,” Society of Behavioral Medicine, Washington, DC, April 6, 2002.

“The Ethics of Assessing Decisionmaking Capacity in CNS Research,” CNS Clinical Trials and Drug Development, Philadelphia, PA, March 19, 2002.

“The Ethics of Placebo-Controlled Trials in Psychiatric Research,” CNS Clinical Trials and Drug Development, Philadelphia, PA, March 18, 2002.

“The Ethics of Randomized Clinical Trials,” National Institute of Dental and Craniofacial Research, Bethesda, MD, December 12, 2001.

“The Ethics of Placebo-Controlled Trials,” National Institutes of Health, Ethical and Regulatory Aspects of Human Subjects Research, Bethesda, MD, November 14, 2001.

“The Rationale for Independent Capacity Assessment,” American Society for Bioethics and Humanities, Nashville, TN, October 25, 2001.

“Addressing Ethical Issues in the Medical Research Literature,” American Society for Bioethics and Humanities, Nashville, TN, October 28, 2001.

“The Ethics of Placebo-Controlled Trials,” Dalhousie University, Halifax, Canada, Workshop on Placebo Controls in Clinical Trials, September 24, 2001.

“The Ethical Challenge of Psychiatric Challenge Studies,” Max-Planck Institute for Psychiatry, Munich, Germany, June 27, 2001.

“Ethics of Placebo-Controlled Trials in Psychiatry,” New Clinical Drug Evaluation Unit, Phoenix, Arizona, May 30, 2001

“Placebo-controlled Trials in Psychiatric Research: An Ethical Perspective,” American Academy of Pharmaceutical Physicians, Baltimore, MD, October 30, 2000.

“Ethics of Randomized Clinical Trials,” National Cancer Institute, Fundamentals of Clinical Trials, October 14, 2000.

“Defining the Ethical Issues in Randomized Clinical Trials,” Society of Surgical Oncology Annual Cancer Symposium, New Orleans, Louisiana, March 17, 2000.

“Placebo-controlled Trials in Psychiatric Research: An Ethical Perspective,” Grand Rounds in Psychiatry, Cornell University Medical School, January 12, 2000.

“The Ethical Challenge of Human Challenge Models,” National Institute of Allergy and Infectious Diseases, Development of a Standardized *Helicobacter pylori* Human Challenge Model Suitable for Studies of Pathogenesis and Vaccine Efficacy, November 30, 1999.

“Professional Integrity in Psychiatric Research,” NIMH Fellows Seminar, May 25, 1999.

“Advertising in Clinical Research,” NIH IRB bioethics consultants, April, 27, 1999.

“Ethical Issues in Psychiatric Research: Placebos and Drug Washouts,” NIMH Fellows Seminar, July 28, 1998.

"Professional Integrity in Clinical Research," paper (co-authored with D.L. Rosenstein and E.G. DeRenzo), NIH Department of Clinical Bioethics Journal Club, April 22, 1998.

"Safeguards for Physician-Assisted Suicide, Fair Oaks Hospital, Fairfax Virginia, March 25, 1998.

"Professional Integrity in Clinical Research," Kennedy Institute of Ethics Seminar for Scholars and Fellows, February 10, 1998.

"The Ethical Challenge of Challenge Studies," Center for Bioethics, University of Pennsylvania, December 5, 1997.

"Clinical Pragmatism and Reform of Clinical Pragmatism," with J.J. Fins, The Joint Meeting of the American Association of Bioethics, Society for Bioethics Consultation, and Society for Health and Human Values, Baltimore, MD, November 7, 1997.

Comments on draft legislation concerning research with decisionally incapacitated individuals developed by Maryland Attorney General's Research Working Group, at conference sponsored by University of Maryland School of Law, May 28, 1997.

"Voluntary Death by Terminal Dehydration Versus Physician-Assisted Suicide," AMA-MSS Sectional Conference, University of Maryland School of Medicine, February 22, 1997.

"Voluntary Death by Terminal Dehydration," paper (co-authored with Diane Meier) presented at Kennedy Institute of Ethics Seminar for Scholars and Fellows, February 11, 1997.

"Regulating Physician-Assisted Suicide: The Oregon Referendum, The Circuit Court Opinions, and the Future," Death with Dignity Leaders' Forum, San Francisco, April 28, 1996.

"A Communitarian Approach to Physician-Assisted Death," paper presented at Kennedy Institute of Ethics Seminar for Scholars and Fellows, February 20, 1996.

Member of panel on Physician-Assisted Death, Metropolitan Washington Bioethics Network, January 27, 1996.

"A Communitarian Approach to Physician-Assisted Death," Death with Dignity Leaders' Forum, Seattle, Washington, January 21, 1996.

"Reconstruction of Hospital Care for Dying Patients," The New York Hospital Medical Ethics Committee, December 13, 1995

Member of panel discussing cases concerning ethics of medical research at Tri-Institutional Ethics Course: Sloan-Kettering Institute, Cornell University Medical College, and Rockefeller University, January 7, 1997 and October 31, 1995.

"Regulating Physician-Assisted Death: Oregon and Beyond," University of Maryland Medical System, Medical Humanities Hour, June 8, 1995.

"Regulating Physician-Assisted Death," Martha Jefferson Hospital, Ethics Committee Educational Forum, Charlottesville, Virginia, April 12, 1995.

"The Regulation of Physician-Assisted Death," Georgetown University Bioethics Colloquium, December 13, 1994.

Keynote Speaker, Forum on Physician-Assisted Death, The Memorial Society of Maryland, November 19, 1994.

"The Limits of Justified Physician-Assisted Death," American Society of Law, Medicine & Ethics 1994 annual meeting, October 7, 1994.

"Regulation of Physician-Assisted Death," Hemlock Society of the National Capital Area, November 14, 1993.

"The Case for Legalized Euthanasia," Fairfax Hospital, Annual Ethics Conference: Euthanasia Pros and Cons, April 27, 1993.

"Safeguards to Prevent Abuse in Legalized Euthanasia," The Emory University Program on Quality of Life, Symposium: Death with Dignity: Is Palliative Care Enough?, February 13, 1993.

"The Case for Legalized Euthanasia," The American Medical Student Association Annual Convention, March 21, 1992.

## PEER REVIEWS

The New England Journal of Medicine

Journal of the American Medical Association  
Annals of Internal Medicine  
Science  
The Journal of General Internal Medicine  
The American Journal of Medicine  
Archives of General Psychiatry  
Biological Psychiatry  
The American Journal of Psychiatry  
The Hastings Center Report  
Milbank Quarterly  
The Journal of Medicine and Philosophy  
The Journal of Clinical Ethics  
Cancer Control  
The Lancet  
Pediatrics  
IRB  
Theoretical Medicine and Bioethics  
American Journal of Bioethics  
The Journal of Medical Ethics  
The American Journal of Respiratory and Critical Care Medicine  
Perspectives in Biology and Medicine  
Kennedy Institute of Ethics Journal  
Clinical Trials  
Lancet Neurology  
Canadian Medical Association Journal  
Social Science & Medicine  
CNS Drugs  
Journal of Clinical Oncology  
Journal of Clinical Epidemiology  
Intensive Care Medicine  
Accountability in Research  
Drug Discovery Today  
Biomed Central: Health Services Research  
Clinical Pharmacology & Therapeutics  
Journal of Psychosomatic Research  
Journal of Empirical Research on Human Research Ethics  
Developing World Bioethics  
Gastroenterology  
Nature Reviews Clinical Oncology  
Trials  
Journal of Theoretical and Philosophical Psychology  
The Journal of Pain and Symptom Management  
International Journal of Epidemiology  
AJOB Empirical Bioethics  
Nous

Synthese  
The Journal of Pain  
PLoS Medicine  
Harvard University Press

#### FELLOWSHIPS

- 2002- Fellow, Hastings Center
- 2001- Faculty Affiliate, Kennedy Institute of Ethics
- 1994-2001 Senior Research Fellow, Kennedy Institute of Ethics

#### EDITORIAL

- 2015- Deputy Editor, *Perspectives in Biology and Medicine*
- 2014-2015 Associate Editor, *Perspectives in Biology and Medicine*
- 2003-2009 Editorial Board, *American Journal of Bioethics*

#### BOARD MEMBERSHIPS

- 1996-1997 Board of Directors, Choice in Dying, New York, NY
- 1995-1997 Board of Directors, Death with Dignity Education Center, San Mateo, CA

#### OTHER PROFESSIONAL ACTIVITIES

- 2015- Scientific Advisor, Foundation for the Science of the Therapeutic Encounter, Cambridge, MA.
- 1997-1998 University of Pennsylvania, Center for Bioethics, Assisted Suicide Panel

#### PROFESSIONAL RECOGNITION

Thomson Reuters Highly Cited Researchers, top one percent of most cited authors of papers indexed in Web of Science in the field of Social Sciences, general, October 2014

#### PROFESSIONAL ASSOCIATIONS

American Society for Bioethics and Humanities